Pharmcodynamics (PD) and Pharmacokinetics (PK) of E7389 (Eribulin, Halichondrin B Analog) During a Phase I Trial in Patients with Advanced Solid Tumors: A California Cancer Consortium Trial

BACKGROUND: The California Cancer Consortium completed a Phase I trial of E7389 (eribulin mesylate), an analog of the marine natural product halichondrin B. This trial was to determine the pharmacodynamics, pharmacokinetics, and MTD of E7389 administered by bolus injection weekly for three weeks out...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Morgan, Robert J., Synold, Timothy W., Longmate, Jeffrey A., Quinn, David I, Gandara, David, Lenz, Heinz-Josef, Ruel, Christopher, Xi, Bixin, Lewis, Michael D., Colevas, A. Dimitrios, Doroshow, James, Newman, Edward M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694049/
https://ncbi.nlm.nih.gov/pubmed/26362045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-015-2868-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados